Multi-modality Imaging in Acute Myocardial Infarction



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:1/6/2019
Start Date:January 20, 2016
End Date:June 2020
Contact:Grace J. San Agustin, RN.
Email:grace.sanagustin@beaumont.org
Phone:248 551 7835

Use our guide to learn which trials are right for you!

The goal of this study is to use three (3) different imaging techniques:Fractional Flow
Reserve (FFR) allows precise measurement of blood flow in the arteries to the heart, and is
more reliable than pictures alone to determine the significance of blockages in the heart;
Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about
the amount of lipid and cholesterol in the plaque, and plaque volume; and Optical Coherence
Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque
thickness; to evaluate high risk non-infarct-related coronary lesion in patients who have
suffered a recent heart attack, underwent successful opening of the artery with a stent, and
have blockages greater than or equal to 50% in one or more of the other arteries to the
heart; and to correlate this findings with cardiovascular outcomes at 1 year.

This is a prospective, open-label, single center registry. The study is designed to
characterize plaque (i.e., assess vulnerable plaque features such as plaque tears, plaque
thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have
suffered a recent acute heart attack, and who have blockages >50% in one or more of the other
arteries in the heart. The procedure to do this will not be the same procedure that was done
to open the artery that caused the heart attack, but will be scheduled 2-40 days after the
first procedure, depending on the urgency to evaluate the other arteries and the stability of
the patient after the first procedure. The study will specifically evaluate the plaque
characteristics in the arteries that didn't cause the heart attack, to see if these arteries
have vulnerable plaque and is at risk for future heart attacks. If FFR shows abnormal blood
flow, these arteries will be treated with stents. All patients will be followed for 12 months
after the second catheterization. The purpose of the study is to determine how commonly
vulnerable plaques are identified in patients with acute heart attacks, and how often these
lead to future cardiac problems. Identification of plaque features that lead to future
problems may allow the development of new medications and devices to prevent future heart
attacks and death. These same plaque features are also thought to be operative in patients
with blockages in the arteries to the brain, so this study may have important implications
for stroke prevention as well. All patients will be considered eligible for participation if
they had a recent acute heart attack resulting from complete occlusion of an artery to the
heart, if the stent procedure to open the artery was successful, and if they have blockages >
50% in at least one other major heart artery. Patients will not be eligible for participation
if they are too unstable with regard to heart, lung, brain, or kidney function, or if they
have previous bypasses to the heart.

In selected patients, Coronary CT Angiography (CCTA) will be performed after the initial
procedure to open the artery within 40 days. CCTA images will be evaluated for plaque
characteristics, and correlated with the invasive findings.Fractional flow reserve via
computed tomography (FFRCT), a non-invasive computed tomography method of measuring blood
flow in the blocked arteries; will also be determined and correlated with invasive FFR.

The standard portion of the procedure includes the angiogram (X-ray pictures of the
arteries), FFR (measurement of blood flow in the artery), IVUS and/or OCT (to assess the
diameter of the artery and the size of the stent), medications, and all office visits. The
research portion of the study requires all imaging studies be performed (NIRS IVUS, OCT, FFR)
rather than just one or two of these imaging studies, and the CCTA.

Inclusion Criteria:

All patients with ST-elevation acute myocardial infarction (STEMI) and age > 18 years who
meet all of the following criteria:

- Successful primary Percutaneous Intervention (PCI) of the Infarcted Related Artery
(IRA) defined as final stenosis < 30%, Thrombolysis In Myocardial Infarction (TIMI) 3
flow

- At least 1 non-IRA with diameter stenosis ≥ 50% and reference vessel diameter > 2mm

- None of the exclusion criteria

Exclusion Criteria:

Patients will be excluded if any of the following are present:

- Cardiogenic shock that persists > 24 hours after primary PCI

- Diffuse disease in non-IRA that precludes successful stenting

- Estimated Glomerular Filtration Rate (eGFR) < 30 cc/min/1.73 m2 after hydration or
optimization of Congestive Heart Failure (CHF) for cardiac death

- eGFR <60 cc/min/1.73 m2, will be in the MIAMI study for invasive imaging treatment
group/cohort but will not get the coronary CCTA

- eGFR < 60 cc/min/1.73 m2, for coronary CCTA

- Active bleeding as defined as a fall in hemoglobin (HGB) concentration > 3 g/dL within
24 hours requiring blood transfusion, vasopressors to maintain Systolic BP > 100mmhg,
or emergency surgical, endovascular, or endoscopic intervention.

- Mechanical complication of MI such as severe Mitral-Valve Regurgitation (MR),
Ventricular Septal Defect (VSD) or pulmonary edema

- Uncontrolled Ventricular Tachycardia (VT) after primary PCI

- Inability to provide informed consent

- Ventilator-dependent respiratory failure

- Only non-IRA is a chronic total occlusion

- Non-IRA is in a Saphenous Vein Graft (SVG) or arterial graft

- Non-IRA is in the left main, ostial Left Anterior Descending (LAD), or ostial Left
circumflex (LCX)

- Non-IRA includes a bifurcation with side branch > 2mm, medina 1-1-1

- Need for multivessel primary PCI during the index procedure
We found this trial at
1
site
3601 West 13 Mile Road
Royal Oak, Michigan 48073
Principal Investigator: Robert Safian, MD
Phone: 248-898-5580
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials